SLC5A2 and type 2 diabetes mellitus: The successful sodium-glucose co-transporter SGLT2 inhibitors used for the treatment of type 2 diabetes illustrate how specific SLCs inhibitors can be developed by extending the molecule from the substrate-binding pocket to interact with gating regions to inhibit transport [50].